8-K filing — MetaVia Inc. (MTVA)
Filed: 2026-09-09 AccNo: 0001104659-26-106156 Size: 235 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
MetaVia Says Preclinical Tissue Distribution Study Showed Highest DA-1726 Exposure In Adipose Tissue And Prolonged Tissue Retention Through 144 Hours; Says 16-Week Topline Data Expected In Q4, 24-Week Results In Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 68.53 percent increase over losses of $(2.86) per share from the
MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts